Enzo Biochem, Inc. ($0.01 Par Value) (ENZ) News

Enzo Biochem, Inc. ($0.01 Par Value) (ENZ)

Today's Latest Price: $1.82 USD

0.14 (-7.14%)

Updated Oct 30 7:00pm

Add ENZ to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 58 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

Filter ENZ News Items

ENZ News Results

Event/Time Symbol Company News Detail Start End Change POWR Rating
Loading, please wait...

Latest ENZ News From Around the Web

Below are the latest news stories about Enzo Biochem Inc that investors may wish to consider to help them evaluate ENZ as an investment opportunity.

Edited Transcript of ENZ earnings conference call or presentation 8-Jun-20 9:00pm GMT

Q3 2020 Enzo Biochem Inc Earnings Call

Yahoo | August 3, 2020

Enzo Biochem to provide COVID-19 testing at 50+ New York pharmacies

Enzo Biochem ([[ENZ]] -0.6%) partners with Community Pharmacy Enhanced Services Network, to provide COVID-19 testing at 52 of the network’s 155 pharmacies across New York State.The company will provide the full range of services, including reagent manufacturing capabilities, diagnostic instruments, and clinical laboratory services....

Seeking Alpha | July 21, 2020


NEW YORK, NY, July 21, 2020 -- Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostic company, and Community Pharmacy Enhanced Services Network (CPESN® NY), the.

Yahoo | July 21, 2020

Do Insiders Own Lots Of Shares In Enzo Biochem, Inc. (NYSE:ENZ)?

The big shareholder groups in Enzo Biochem, Inc. (NYSE:ENZ) have power over the company. Institutions will often hold...

Yahoo | July 17, 2020

Enzo Biochem shares rise on FDA authorization for coronavirus test

Shares of Enzo Biochem Inc. rallied 7.7% in premarket trading on Monday after the company said it received an emergency use authorization from the Food and Drug Administration for its COVID-19 diagnostic test. The regulator issued the EUA on July 7. It has granted emergency authorization to at least 137 diagnostic tests during the COVID-19 pandemic. Enzo's stock is up 8.7% year-to-date. The S&P 500 has declined 1.4% since the start of the year.

Yahoo | July 13, 2020

Enzo Biochem Receives Emergency Use Authorization for Proprietary Test System for Detection of Coronavirus SARS-CoV-2

Flexible Use on Three Platforms including Enzo’s Proprietary Automated GENFLEX™ Platform  NEW YORK, NY, July 13, 2020 -- Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences.

Yahoo | July 13, 2020

Enzo Biochem's COVID test granted emergency authorization from the FDA

Enzo Biochem (ENZ) soared 21% yesterday as its Ampiprobe SARS-CoV-2 Test System was granted Emergency Use Authorization by the FDA in a letter.The letter stated, "based on the totality of scientific evidence available to FDA, it is reasonable to believe that your product may be effective in diagnosing COVID-19, and that...

Seeking Alpha | July 9, 2020

Enzo Biochem to Provide COVID-19 Testing to Farmingdale State College Staff and Students as They Return to Campus

Enzo Biochem, Inc. (ENZ), a leading biosciences and diagnostic company, and Farmingdale State College today announced they are partnering to provide molecular and antibody testing for COVID-19 to the campus community as the college reopens this summer and begins classes in the fall. “This program fits perfectly into this fall’s campus plans designed by our COVID-19 Task Force, and testing our students with no required financial outlay is important,” said Farmingdale State College President John S. Nader. Testing by Enzo is a component of Farmingdale’s comprehensive fall campus plan, which also includes mandatory face coverings, social distancing, and delivery of classes through a combination of face-to-face, remote learning, and online instruction.

Yahoo | June 30, 2020

Should You Avoid Enzo Biochem, Inc. (ENZ)?

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each […]

Yahoo | June 25, 2020

Enzo Announces Issuance of U.S. Patent for Methods of Treating Liver Cancer Using Proprietary Compound SK1-I

Enzo Biochem, Inc. (ENZ), a leading biosciences and diagnostics company, today announced it has received a patent for the treatment of liver cancer, U.S. Patent No. 10,675,255 entitled Sphingosine Pathway Modulating Compounds for the Treatment of Cancers. Enzo’s patent is directed to methods for treating hepatocellular carcinoma (HCC), the most common human liver cancer, using the company’s proprietary compound SK1-I and has a term extending into June 2038.

Yahoo | June 23, 2020

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7297 seconds.